Knokke-Heist (Belgium), 25 February 2026, 6:00 a.m.; bonyf NV (Ticker: MLBON), a leader in dental consumer goods, professional dental consumables and dermatological solutions, today provides a strategic business update regarding its flagship professional product PerioCream^®.

The Company is pleased to confirm the continued and steady commercial progression of PerioCream^® across multiple European markets. Adoption within professional dental protocols is advancing in line with expectations, supported by ongoing distributor onboarding and clinical-driven demand from dental practitioners.

In parallel, bonyf is actively engaged in advanced discussions with potential commercial partners in China, representing a significant opportunity for future expansion outside Europe. These discussions form part of the Company’s broader internationalization strategy aimed at establishing PerioCream^® as a globally recognized post-treatment barrier solution within periodontal care.

Update on Planned Nasdaq Listing

Following a comprehensive strategic review, Bonyf has decided to discontinue the previously announced planning process for a potential Nasdaq listing.

This decision has been taken in light of:

• Increasing complexity related to evolving international tariff frameworks;
• Heightened regulatory uncertainty impacting cross-border listing environments;
• Significantly rising advisory, legal and compliance costs associated with the listing process.

Given the current macro-economic and geopolitical landscape, the Board of Directors believes that redirecting financial and operational resources toward commercial development and revenue generation represents the most prudent course of action in the best interests of shareholders.

Strategic Focus Going Forward

bonyf will therefore intensify its focus on:

• Global sales acceleration of PerioCream^®.
• Expansion of professional dental distribution networks.
• Market entry into high-growth regions outside Europe.
• Operational scale-up to meet increasing product demand.

Management remains confident that concentrating on core commercial execution will drive sustainable growth and long-term shareholder value creation.

bonyf’s strengths

• Products with patented formulations
• Produced in Switzerland compliant with stringent international quality regulations
• Proven clinical efficacy
• Commercial presence in 37 countries
• Prospects for solid growth and rapid profitability
• A fast-growing oral and dental care market